CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

CHICAGO — In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according to new data from the SURMOUNT-1 study. As Healio previously ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...

When it comes to weight loss, providers and patients argue that GLP-1 medications are not a one-for-one swap and that volatile insurance coverage contradicts the science and experience of people ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

3. Zepbound Zepbound is Mounjaro’s weight loss-approved counterpart. It’s another brand name for tirzepatide. Zepbound comes in the same dose as Mounjaro and works in the same way. The only ...